Home › Compare › ARUXF vs O

ARUXF vs O: Dividend Comparison 2026

ARUXF yields 44444.44% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARUXF wins by $1.4802188700273396e+23M in total portfolio value
10 years
ARUXF
ARUXF
● Live price
44444.44%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4802188700273396e+23M
Annual income
$147,369,615,738,581,320,000,000,000,000.00
Full ARUXF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ARUXF vs O

📍 ARUXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARUXFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARUXF + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ARUXF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARUXF
Annual income on $10K today (after 15% tax)
$3,777,777.78/yr
After 10yr DRIP, annual income (after tax)
$125,264,173,377,794,110,000,000,000,000.00/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, ARUXF beats the other by $125,264,173,377,794,110,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARUXF + O for your $10,000?

ARUXF: 50%O: 50%
100% O50/50100% ARUXF
Portfolio after 10yr
$7.401094350136698e+22M
Annual income
$73,684,807,869,290,660,000,000,000,000.00/yr
Blended yield
99.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ARUXF
No analyst data
Altman Z
-46.1
Piotroski
3/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARUXF buys
0
O buys
0
No recent congressional trades found for ARUXF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARUXFO
Forward yield44444.44% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$1.4802188700273396e+23M$34.2K ✓
Annual income after 10y$147,369,615,738,581,320,000,000,000,000.00 ✓$5,102.74
Total dividends collected$1.4797905017086652e+23M$20.7K ✓
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: ARUXF vs O ($10,000, DRIP)

YearARUXF PortfolioARUXF Income/yrO PortfolioO Income/yrGap
1← crossover$4,455,144$4,444,444.44$10,818$608.16+$4.44M → ARUXF
2$1,855,294,292$1,850,527,287.41$11,787$741.68+$1855.28M → ARUXF
3$722,201,114,647$720,215,949,754.98$12,946$911.00+$722201.10M → ARUXF
4$262,786,638,114,837$262,013,882,922,164.10$14,345$1,127.94+$262786638.10M → ARUXF
5$89,382,811,928,504,960$89,101,630,225,722,080.00$16,056$1,409.05+$89382811928.49M → ARUXF
6$28,419,510,536,946,614,000$28,323,870,928,183,110,000.00$18,171$1,777.83+$28419510536946.60M → ARUXF
7$8,446,906,587,814,894,000,000$8,416,497,711,540,360,000,000.00$20,820$2,268.21+$8446906587814894.00M → ARUXF
8$2,346,953,255,508,951,600,000,000$2,337,915,065,459,989,300,000,000.00$24,188$2,929.90+$2346953255508951552.00M → ARUXF
9$609,599,312,292,179,560,000,000,000$607,088,072,308,785,000,000,000,000.00$28,533$3,837.11+$609599312292179607552.00M → ARUXF
10$148,021,887,002,733,950,000,000,000,000$147,369,615,738,581,320,000,000,000,000.00$34,235$5,102.74+$1.4802188700273396e+23M → ARUXF

ARUXF vs O: Complete Analysis 2026

ARUXF — Stock

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Full ARUXF Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ARUXF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARUXF vs SCHDARUXF vs JEPIARUXF vs KOARUXF vs MAINARUXF vs STAGARUXF vs ADCARUXF vs NNNARUXF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.